Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer

Doki Y.Ueno M.CHIH-HUNG HSUOh D.-Y.Park K.Yamamoto N.Ioka T.Hara H.Hayama M.Nii M.Komuro K.Sugimoto M.Tahara M.2022-08-192022-08-1920222045-7634https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130423959&doi=10.1002%2fcam4.4593&partnerID=40&md5=a983666b144e577f24ded4d18b7390bdhttps://scholars.lib.ntu.edu.tw/handle/123456789/617256[SDGs]SDG3Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancerjournal article10.1002/cam4.4593356114992-s2.0-85130423959